Set price fees for R&D Tax Incentive claims and advance findings
Tuesday, 01 May, 2012
Three tax-specialist accounting firms are offering AusBiotech members free consultations and set prices for R&D Tax Incentive claims and advance findings to provide certainty for biotechnology and medtech companies.
The offers from BDO, Grant Thornton and MPR Group are in response to a recent submission to AusIndustry, where AusBiotech conveyed member feedback suggesting the Government “consider brokering a set price assessment by a list of tax specialist consultants”, as AusBiotech is aware that many small companies have not sought advice due to unknown costs, which are assumed to high.
The subsequent release of the 2012 Biotechnology Industry Position Survey showed that 53% of respondents had not yet sought professional advice on the impact or opportunity presented by the new R&D Tax Incentive.
AusBiotech-member accounting firms, who specialise in tax, would like to offer set price arrangements:
- Initial assessment of eligibility and claim estimate;
-
- Preparation of a claim; and/or
-
- Application for advanced finding
See the AusBiotech website for contact and further details: www.ausbiotech.org.
| Initial assessment of eligibility and claim estimate | Preparation of a claim | Advanced or Overseas Finding application | |
| BDO | Free | $5,000 per project | Time and materials capped at $10,000 per application |
| Grant Thornton | Free | Group turnover: $10m or less: $8,500; $10m-$20m: $12,000; $20m-$50m: $17,500; Over$50m: $35,000 | $9,500 per application |
| MPR Group | Free (up to 2 hours) | $10,000 for first project and $5,000 for each additional project (in one year) | $5,000 per application |
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...

